Simon J. Hall
- ASSOCIATE PROFESSOR Urology
American Board of Urology
MD, Columbia Univ. Col. of Phy. & Surg.
Mount Sinai Hospital
Boston University Medical Center
Baylor College of Medicine
Dr. Hall is Director of the Barbara and Maurice Deane Prostate Health and Research Center.
My clinical interests are primarily urologic oncology, specifically the diagnosis, evaluation and treatment of prostate cancer, renal cell cancer and urothelial (transitional cell) cancer affecting the kidneys and bladder. In the area of prostate cancer I am especially interested in the use of multimodal therapy for the treatment of high risk cancer and of novel therapies in the treatments of disease recurrence following definitive treatment. In the area of urothelial cancers of the kidney and renal cell carcinomas I am interesed in further development of the use of laparoscopy and other minimally invasive treatment such as percutaneous cryotherapy for the treatment of selected renal lesions. In the area of bladder cancer I am interested in the use of robotics to decrease the morbidity by removing the bladder and in reconstructive techniques to remake a new bladder out of intestine so that an individual patient's quality of life after surgery will be as close to that pre-surgery.
Dr. Hall discusses his work with prostate cancer screenings in The Daily News feature The Daily Check Up. View the PDF.
Read the commentary by Simon J. Hall, MD, William K.Oh, MD, David B. Samadi, MD, and Richard G. Stock, MD, "Fighting Round Two: Recurrent Prostate Cancer" that appeared in the The New York Times on June 8, 2010.
Castle Connolly - New York Magazine
Castle Connolly -New York Magazine
Castle Connolly - New York Magazine
Castle Connoll - New York Magazine
Castle Connolly - New York Magazine
For the most part, my research interests both clinically and in the laboratory have focused on prostate cancer. My laboratory in the Department of Cell and Gene Medicine is focused on the development of novel therapies for cancer. A major initiative is the use of novel viruses such as VSV (vesicular stomatitis virus) to target and preferentially eliminate prostate and bladder cancer cells while sparing normal cells as a form of therapy for locally advanced or recurrent prostate cancer. We are also performing a Phase I clinical trial using an adenovirus expressing Interleukin 12 in patients with locally advanced recurrent cancer in an effort to stimulate immune responses against not just local cancer but microscopically present metastatic diseases. Our second initiative is focused on a novel co-chaperone called CHIP in androgen receptor expressing hormone refractory prostate cancer cells results in cell death while causing only growth inhibition of hormone sensitive cells. We are exploring the hypothesis that such manipulation may be anovel therapeutic approach for perhaps preventing and/or treating hormone refractory prostate cancer.
Clinically, as Director of the Deane Prostate Health and Research Center I am most interested in expanding multi-departmental and multidisciplinary research approaches in the diagnosis and treatment of patients with prostate cancer through a variety of clinical efforts and research clinical trials. I have a personal interest in prostate cancer patients at opposite ends of the clinical patients with a high likelihood of having clinically insignificant prostate cancer. These patients would be excellent candidates for expectant management, an active program whereby patients are closely followed by physical exam, PSA levels and confirmatory/surveillance biopsies so overtime patients with higher volume or grade disease or progressive disease can opt for definitive treatment without risking disease failure while the remainder will remain on a no treatment scheme. For patients with more advanced and recurrent diseases we have designed a variety of escalating choices for treatment through industry sponsored clinical trials such as Dendritic cell vaccines and our own in-house clinical trials.
Mock S, Leapman M, Stock R, Hall S, Stone N. Risk of Urinary Incontinence following Post-Bracytherapy Transurethral Resection of the Prostate (TURP) and Correlation with Clinical and Treatment Parameters. J Urology 2013 May ;.
Leapman M, Hall S, Stock R, Stone N. Haematuria after prostate brachytherapy. BJU Int. 2013 January;.
Tsao C, Small A, Kates M, Moshier E, Wisnivesky J, Gartrell B, Sonpavde G, Godbold J, Palese M, Hall S, Oh W, Galsky M. Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the united States: a SEER analysis. World J Urol 2012 December;.
Mohamed NE, Bovbjerg DH, Montgomery GH, Hall SJ, Diefenbach MA. Pretreatment depressive symptoms and treatment modality predict post-treatment disease-specific qulaity of life among patients with localized prostate cancer. Urologic oncology 2011 Juky;(E-Pub).
Tsao C, Small A, Moshier E, Gartrell B, Wisnivesky J, Sonpavde G, Godbold J, Palese M, Hall S, Oh W, Galsky M. Trends in the use of cytoreductive nephrectomy in the United States. Clin Genitourin Cancer 2012 Sep;(3): 159-63.
Small A, Tsao C, Moshier E, Gartrell B, Wisnivesky J, Godbold J, Sonpavde G, Palese M, Hall S, Oh W, Galsky M. Trends and variations in utilization of nephron-sparing procedures for stage 1 kidney cancer in the United States. World J Urol 2012 May;.
Small A, Gong Y, Oh W, Hall S, CJ v, Galsky M. The emerging role of circulating tumor cell dertection in genitourinary cancer. J Urol 2012 Jul;: 21-6.
Diefenbach M, Mohamed N, Butz B, Bar-Chama N, Stock R, Cesaretti J, Hassan W, Samadi D, Hall S. Acceptability and preliminary feasibility of an Internet/CD-ROM-based education and decision program for early-stage prostate cancer patients: randomized pilot study. J Med internet Research 2012 Jan;.
Hall SJ, Klotz L, Pantuck AJ, George DJ, Whitmore JB, Frohlich MW, Sims RB. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipeleucel-T in patients with prostate cancer. Journal of Urology 2011 September; 186(3): 877-881.
Mohamed N, Bovbjerg D, Montgomery G, Hall S, Diefenbach M. Pretreatment depressive symptoms and treatment modality predict post-treatment disease specific qulaity of life among patients with localized prostate cancer. Urol Oncology 2012 Nov-Dec; 30(6): 804-12.
Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, Schellhammer PF, Jones LA, Xu Y, Kylstra JW, Frohlich MW. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clinical Cancer Research 2011 July 1; 17(13): 4558-4567.
Phalen A, Akhavan A, Hall S. Mullerian remnant malignancy. Urology 2012 Mar; 79(3): 38-9.
Galsky MD, Hall SJ, Schellhammer PF, Jones LA, Xu Y, Kylstra JW, Frohlich MW. Bladder Cancer: current management and opportunities for a personalized approach. Mt. Sinai J. Med 2010 Nov-Dec.; 77(6): 587-596.
Davis SN, Diefenbach MA, Valdimarsdottir H, Chen T, Hall SJ, Thompson HS. Pros and cons of prostate cancer screening: associations with screening knowledge and attitudes among urban African American men. J Natl Med Assoc. 2010 March; 102(3): 174-182.
Shelton RC, Winkel G, Davis SN, Roberts N, Valdimarsdottir H, Hall SJ, Thompson HS. Validation of the group-based medical mistrust scale among urban black men. J Gen Intern Med. 2010 June; 25(6): 549-555.
Stock RG, Yalamanchi S, Hall SJ, Stone NN, Valdimarsdottir H, Hall SJ, Thompson HS. Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation. Journal of Urology 2010 Feb.; 183(2): 546-550.
Stock RG, Cesaretti JA, Hall SJ, Stone NN. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU Int. 2009 Dec.; 104(11): 1631-1636.
Stock RG, Cesaretti JA, Hall SJ, Stone NN. .;.
- A Randomized, Phase 2, Open Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma
- A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer
- An open-label multicenter study of Sipuleucel-T in metastatic castrate resistant prostate cancer patients previously treated with Sipuleucel-T on Dendreon Study P-11
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Hall during 2012 and/or 2013. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Gerson Lehrman Group
Scientific Advisory Board:
- Armada Health Care; Bayer; Dendreon Corporation
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- Cadent Medical Communications
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Faculty Practice Associates
5 East 98th Street,6th Floor
New York, NY 10029
5 East 98th Street
New York, NY 10029